We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
Notice for dasatinib (Bristol-Myers Squibb Australia Pty Ltd)
Active ingredients
dasatinib
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Tablet, film-coated
Indication
For the treatment of paediatric patients with chronic myeloid leukaemia
Therapeutic area
Haematology